Adma Biologics reported $50.4M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Adma Biologics USD 50.4M 8.24M Dec/2025
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Novavax USD 22.1M 608K Dec/2025
Omeros USD 33.16M 18.52M Jun/2024
Takeda JPY 560.54B 159.39B Mar/2026